Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 01.11.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | s of Certain Officers. This is an amendment to Item 5.02 of the Current Report on Form 8-K that was filed by Waters Corp |
Stammdaten
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by life science, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
Unternehmen & Branche
| Name | WATERS CORP /DE/ |
|---|---|
| Ticker | WAT |
| CIK | 0001000697 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Diagnostics & Research |
| SIC | 3826 · Laboratory Analytical Instruments |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 17,29 Mrd. USD |
| Beta | 1,20 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 3,165,286,000 | 642,629,000 | 10.76 | 5,076,550,000 | 2,561,242,000 |
| 2025-09-30 | 10-K | 799,887,000 | 2.50 | |||
| 2025-09-27 | 10-Q | 799,887,000 | 148,923,000 | 2.50 | 4,862,564,000 | 2,330,693,000 |
| 2025-06-30 | 10-K | 771,332,000 | 2.47 | |||
| 2025-06-28 | 10-Q | 771,332,000 | 147,111,000 | 2.47 | 4,718,075,000 | 2,159,812,000 |
| 2025-03-31 | 10-K | 661,705,000 | 2.03 | |||
| 2025-03-29 | 10-Q | 661,705,000 | 121,381,000 | 2.03 | 4,591,576,000 | 1,962,397,000 |
| 2024-12-31 | 10-K | 872,714,000 | 637,834,000 | 3.88 | 4,553,795,000 | 1,828,507,000 |
| 2024-09-30 | 10-K | 740,305,000 | 2.71 | |||
| 2024-09-28 | 10-Q | 740,305,000 | 161,503,000 | 2.71 | 4,511,620,000 | 1,603,099,000 |
| 2024-06-30 | 10-K | 708,529,000 | 2.40 | |||
| 2024-06-29 | 10-Q | 708,529,000 | 142,737,000 | 2.40 | 4,449,047,000 | 1,411,967,000 |
| 2024-03-31 | 10-K | 636,839,000 | 1.72 | |||
| 2024-03-30 | 10-Q | 636,839,000 | 102,196,000 | 1.72 | 4,508,964,000 | 1,256,525,000 |
| 2023-12-31 | 10-K | 819,474,000 | 642,234,000 | 3.65 | 4,626,854,000 | 1,150,341,000 |
| 2023-09-30 | 10-K | 711,692,000 | 2.27 | |||
| 2023-09-30 | 10-Q | 711,692,000 | 2.27 | 4,497,180,000 | 905,522,000 | |
| 2023-07-01 | 10-Q | 740,576,000 | 2.55 | 4,548,196,000 | 771,229,000 | |
| 2023-06-30 | 10-K | 740,576,000 | 2.55 | |||
| 2023-04-01 | 10-Q | 684,674,000 | 2.38 | 3,306,820,000 | 599,823,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-16 | Jiang Wei | Director | Open Market Purchase | 500 | 289.46 | 144,730.00 | +64,2% | |
| 2026-03-06 | FEARON RICHARD H | Director | Open Market Purchase | 1,000 | 306.34 | 306,340.00 | +135,8% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.